Brief report: Enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women

Journal of Acquired Immune Deficiency Syndromes

Volumn 43, Issue 2, 2006, Pages 193-196

  L'Homme, Rafaëlla F A ^a   Dijkema, Tim ^a   Van Der Ven, Andre J A M ^a   Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Drug resistance; Enzyme induction; Half life; Nevirapine

Indexed keywords

CARBAMAZEPINE; COLECALCIFEROL; HYPERICUM PERFORATUM EXTRACT; NEVIRAPINE; PHENOBARBITAL; PHENYTOIN; RETINOL;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HUMAN; INTRAUTERINE INFECTION; NORMAL HUMAN; PRIORITY JOURNAL; SOMNOLENCE; VERTIGO;

ADOLESCENT; ADULT; DRUG RESISTANCE, VIRAL; ENZYME INDUCTION; FEMALE; HALF-LIFE; HUMANS; NEVIRAPINE; PILOT PROJECTS;

EID: 33749016461     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000234089.41785.c8     Document Type: Article

References (22)

1. Nolan ML, Greenberg AE, Fowler MG. A review of clinical trials to prevent mother-to-child HIV-1 transmission in Africa and inform rational intervention strategies. AIDS. 2002;16:1991-1999.
2. Eshleman SH, Jackson JB. Nevirapine resistance after single dose prophylaxis. AIDS Rev. 2002;4:59-63.
3. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis. 2005;192:30-36.
4. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;351:229-240.
5. Jackson JB, Becker-Pergola G, Guay LA, et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS. 2000;14:F111-F115.
6. Mirochnick M, Clarke DF, Dorenbaum A. Nevirapine: pharmacokinetic considerations in children and pregnant women. Clin Pharmacokinet. 2000;39:281-293.
7. Perucca E, Hedges A, Makki KA, et al. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol. 1984;18:401-410.
8. Maat MRD, Hoetelmans RMW, Mathot RAA, et al. Drug interaction between St John's wort and nevirapine. AIDS. 2001;15:420-421.
9. Ruhl R, Sczech R, Landes N, et al. Carotenoids and their metabolites are naturally occurring activators of gene expression via the pregnane X receptor. Eur J Nutr. 2004;43:336-343.
10. Drocourt L, Ourlin JC, Pascussi JM, et al. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem. 2002;277:25125-25132.
11. Mueller SC, Uehleke B, Woehling H, et al. Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther. 2004;75:546-557.
12. Zhou S, Chan E, Pan SQ, et al. Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol. 2004;18:262-276.
13. Bar-Oz B, Nulman I, Koren G, et al. Anticonvulsants and breast feeding: a critical review. Paediatr Drugs. 2000;2:113-126.
14. Giessmann T, May K, Modess C, et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther. 2004;76:192-200.
15. Almond LM, Edirisinghe D, Dalton M, et al. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther. 2005;78:132-142.
16. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-2400.
17. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;15:1-5.
18. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS. 1999;13:479-486.
19. McIntyre JA, Martinson N, Gray GE, et al. Addition of short course Combivir (CBV) to single dose Viramune (sdNVP) for the prevention of mother to child transmission (pMTCT) of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus [abstract 2176901]. Presented at: Third International AIDS Society Conference on HIV Pathogenesis and Treatment; 2005; Rio de Janeiro.
20. Stringer JS, Sinkala M, Maclean CC, et al. Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia. AIDS. 2005;19:1309-1315.
21. Veldkamp AI, Weverling GJ, Lange JMA, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS. 2001;15:1089-1095.
22. Vries-Sluijs TE, Dieleman JP, Arts D, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet. 2003;42:599-605.